Eva Rettinger1, Hermann Kreyenberg2, Michael Merker2, Selim Kuçi2, Andre Willasch2, Gesine Bug3, Evelyn Ullrich4, Winfried S Wels5, Halvard Bonig6, Thomas Klingebiel2, Peter Bader2. 1. University Hospital Frankfurt/Main, Department for Children and Adolescents Medicine, Division of Stem Cell Transplantation and Immunology, Goethe-University Frankfurt/Main, Frankfurt/Main, Germany. Electronic address: eva.rettinger@kgu.de. 2. University Hospital Frankfurt/Main, Department for Children and Adolescents Medicine, Division of Stem Cell Transplantation and Immunology, Goethe-University Frankfurt/Main, Frankfurt/Main, Germany. 3. Department of Medicine II, Hematology, Oncology, Rheumatology and Infectious Diseases, University Hospital Frankfurt/Main, Frankfurt/Main, Germany. 4. University Hospital Frankfurt/Main, Department for Children and Adolescents Medicine, Division of Stem Cell Transplantation and Immunology, Goethe-University Frankfurt/Main, Frankfurt/Main, Germany; LOEWE Center for Cell and Gene Therapy, Frankfurt/Main, Germany. 5. Georg-Speyer-Haus, Institut für Tumorbiologie und experimentelle Therapie Frankfurt/Main, Germany. 6. Institute for Transfusion Medicine and Immunohematology, Goethe-University Frankfurt/Main, German Red Cross Blood Donor Service Baden-Württemberg-Hessen, Division for Cell Processing, Frankfurt/Main, Germany.
Abstract
BACKGROUND AIMS: Cytokine-induced killer (CIK) cells may offer a novel therapeutic approach for patients with malignancies relapsing after allogeneic stem cell transplantation. Although CIK cells display negligible alloreactivity and cause minimal graft versus-host-disease (GVHD), high CIK cell doses required during relapse may pose a risk for severe GVHD, specifically in the mismatched or haploidentical transplantation setting. Manipulation of CIK cells may reduce risk for GVHD without affecting the anti-tumor potential. METHODS: In this pre-clinical study, we provide a detailed functional comparison of conventional and irradiated, CD56-enriched or T-cell receptor α/β-depleted CIK cells. RESULTS: In vitro analysis showed retained anti-leukemic and anti-tumor potential after CIK cell manipulation. Even being sequentially infused into immunodeficient mice grafted with malignant cells, cytotoxic effects were fewest after irradiation but were improved by CD56 enrichment and were best with conventional CIK cells. Hence, considering the proliferative capacity of inoculated malignancies and effector cells, a single dose of conventional CIK cells resulted in prolonged disease-free survival and elimination of rhabdomyosarcoma cells, whereas sequential infusions were needed to achieve comparable results in leukemia-bearing mice. However, this mouse model has limitations: highly effective conventional CIK cells demonstrated both limited xenogenic GVHD and low alloreactive potential in vitro. CONCLUSIONS: Our study revealed that conventional CIK cells demonstrate no significant alloreactive potential but provide the strongest anti-tumor efficacy compared with manipulated CIK cells. Conventional CIK cells may therefore be tested in high numbers and short-term intervals in patients with impending relapse even after mismatched transplantation.
BACKGROUND AIMS: Cytokine-induced killer (CIK) cells may offer a novel therapeutic approach for patients with malignancies relapsing after allogeneic stem cell transplantation. Although CIK cells display negligible alloreactivity and cause minimal graft versus-host-disease (GVHD), high CIK cell doses required during relapse may pose a risk for severe GVHD, specifically in the mismatched or haploidentical transplantation setting. Manipulation of CIK cells may reduce risk for GVHD without affecting the anti-tumor potential. METHODS: In this pre-clinical study, we provide a detailed functional comparison of conventional and irradiated, CD56-enriched or T-cell receptor α/β-depleted CIK cells. RESULTS: In vitro analysis showed retained anti-leukemic and anti-tumor potential after CIK cell manipulation. Even being sequentially infused into immunodeficientmice grafted with malignant cells, cytotoxic effects were fewest after irradiation but were improved by CD56 enrichment and were best with conventional CIK cells. Hence, considering the proliferative capacity of inoculated malignancies and effector cells, a single dose of conventional CIK cells resulted in prolonged disease-free survival and elimination of rhabdomyosarcoma cells, whereas sequential infusions were needed to achieve comparable results in leukemia-bearing mice. However, this mouse model has limitations: highly effective conventional CIK cells demonstrated both limited xenogenic GVHD and low alloreactive potential in vitro. CONCLUSIONS: Our study revealed that conventional CIK cells demonstrate no significant alloreactive potential but provide the strongest anti-tumor efficacy compared with manipulated CIK cells. Conventional CIK cells may therefore be tested in high numbers and short-term intervals in patients with impending relapse even after mismatched transplantation.
Authors: Melanie Bremm; Sabine Huenecke; Olga Zimmermann; Verena Pfirrmann; Andrea Quaiser; Halvard Bonig; Jan Soerensen; Thomas Klingebiel; Eva Rettinger; Peter Bader; Claudia Cappel Journal: J Transl Med Date: 2016-09-13 Impact factor: 5.531